Fresenius Medical Care (FME), announced the launch of the first tranche of its initial EUR 1 billion share buyback, which is part of its new capital allocation framework as presented at its Capital Markets Day on June 17. Today, the first tranche of up to EUR 600 million was initiated, which is planned to be completed at the latest by April 30, 2026.
Also Read: Is Fresenius Medical Care Using AR to Train on Kidney Replacement Therapy Device?
“With the share buyback program, we are rapidly implementing an important component supporting our new FME Reignite strategy. The new program relates to initial share buybacks totaling EUR one billion over two years. This underscores our goal of reigniting value creation for shareholders and enables our shareholders to participate in the strength of our company,” said Helen Giza, CEO of Fresenius Medical Care.
“The implementation of regular share buybacks in addition to a consistent dividend policy is part of our new capital allocation framework,” stated Martin Fischer, CFO of Fresenius Medical Care.
